ライフサイエンスコーパス: mitotane

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 n tumor weight in both xenograft models than mitotane.

2 er overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitota

3 ane (17.1 month) than with streptozocin plus mitotane (4.7 months).

4 erapy is restricted to patients who tolerate mitotane and either experience a clinical response or ar

5 DP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of to

6 th disseminated or residual disease received mitotane, cisplatin, etoposide, and/or doxorubicin, and

7 Moreover, exposure of cells to mitotane, cisplatin, or radiation rapidly induced pro-cM

8 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.

9 response rate than those in the streptozocin-mitotane group (23.2% vs. 9.2%, P<0.001) and longer medi

10 sion-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitota

11 Baseline features in the mitotane group and the control group from Italy were sim

12 For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate

13 o 47 Italian patients after radical surgery (mitotane group), whereas 55 Italian patients and 75 Germ

14 survival was significantly prolonged in the mitotane group, as compared with the two control groups

15 carcinomas (P=0.02) than did patients in the mitotane group.

16 ane group and 2.2 months in the streptozocin-mitotane group.

17 Mitotane has remained the preferred adjuvant treatment a

18 aim was to evaluate the efficacy of adjuvant mitotane in prolonging recurrence-free survival.

19 ected targets were tested in comparison with mitotane in the 2 ACC cell lines (H295R and SW-13) in vi

20 Whether the use of mitotane is beneficial as an adjuvant treatment has been

21 ients, steroidogenesis inhibitors, including mitotane, ketoconazole, metyrapone, and etomidate, shoul

22 Adjuvant mitotane may prolong recurrence-free survival in patient

23 advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg

24 ndomized, controlled trials, adjuvant use of mitotane remains controversial, although the authors of

25 effective doses, most clinicians agree that mitotane should be used if the tumor cannot be removed s

26 ival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-l

27 tion is obtained when DZNep is combined with mitotane, the gold-standard treatment for ACC.

28 ria included previous pasireotide treatment, mitotane therapy within 6 months, and pituitary irradiat

29 Multivariate analysis indicated that mitotane treatment had a significant advantage for recur

30 Adjuvant mitotane was administered to 47 Italian patients after r

31 served when pharmacologic adrenalectomy with mitotane was done in combination with Ad5IL-12 vector tr

32 Adverse events associated with mitotane were mainly of grade 1 or 2, but temporary dose

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。